Gabather AB presents preclinical and clinical data of the Lead Drug Candidate, GT-002, at the American Society for Neurosciences (AfN) meeting in Chicago.

Gabather AB announces that today the company has a poster presentation summarizing the preclinical and clinical data of GT-002 at the AfN meeting in Chicago. The meeting is the biggest scientific meeting within Neurosciences with more than 26 500 international participants. The presentation includes the preclinical data accumulated during the last years as well as clinical data from the previous phase Ia study in healthy volunteers that was finalized in the second quarter of 2019 (Single Ascending Dose study, SAD). ”We are both proud and happy to present our data and research at this